Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR-TKI Resistance in Non-Small Cell Lung Cancer.

Thorac Cancer · 2026 · PMC13098063 · PMID 41825931

Europe PMC DOI

hedged sentence

0.2210

closest p · 4.4× alpha

0.2210

boldest claim

The sentences

did not reach statistical significancep = 0.221not close (p > 0.1)

GZMH exhibited a similar trend, although the difference between expression groups did not reach statistical significance (1.8 months [95% CI, 1.6–1.9 months] versus 2.8 months [95% CI, 2.1–3.5 months]; log‐rank p = 0.221).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.